The mission of the Lombardi Comprehensive Cancer Center (Lombardi) Administration is to facilitate and implement the vision of the center's director and support an environment that fosters collaboration, interaction, and productivity among Cancer Center members. Lombardi's administrative team provides the tools to help Cancer Center leaders effectively plan, meet, make wise strategic investments, evaluate performance, and communicate with various constituencies Inside and outside the Cancer Center. Administration functions with an organizational structure that is aligned with programs and shared resources to best support the Cancer Center director, leadership. Cancer Center membership and research support staff. They track and manage institutional commitments in order to support recruitment, retention, mentoring, and promotion of Cancer Center members. Lombardi administrative services funded by the CCSG exist to provide research infrastructure through administrative operations, program planning, and program development. The achievement and support of programmatic research activities is best supported in an environment that embraces routine Interactions between Cancer Center members and helps develop, evaluate and document the goals and plans of the Director. Furthermore, planning activities around recruitment, technology (shared resources), and space position the Cancer Center to accomplish these goals in a manner that results In quality cancer science. Growth in Lombardi's peer reviewed cancer research resulted In a need to provide more administrative depth than during the last review. Lombardi's administrative structure supporting Cancer Center activities and members now consists of: Mr. Vander Hoek, Associate Director of Administration and Planning, Ms. Brophy, CPA, CFO, Ms. McLaughlin, Research Planning, Ms. Carbott, Research Facilities, and five dedicated program and shared resource staff. This structure Is responsive to the goals of the CCSG.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA051008-19S1
Application #
8536219
Study Section
Subcommittee G - Education (NCI)
Project Start
1997-08-15
Project End
2014-04-30
Budget Start
2012-09-20
Budget End
2013-04-30
Support Year
19
Fiscal Year
2012
Total Cost
$75,000
Indirect Cost
$26,639
Name
Georgetown University
Department
Type
DUNS #
049515844
City
Washington
State
DC
Country
United States
Zip Code
20057
Tassi, Elena; Garman, Khalid A; Schmidt, Marcel O et al. (2018) Fibroblast Growth Factor Binding Protein 3 (FGFBP3) impacts carbohydrate and lipid metabolism. Sci Rep 8:15973
Lipkus, Isaac M; Mays, Darren (2018) Comparing harm beliefs and risk perceptions among young adult waterpipe tobacco smokers and nonsmokers: Implications for cessation and prevention. Addict Behav Rep 7:103-110
Speidell, Andrew P; Demby, Tamar; Lee, Yichien et al. (2018) Development of a Human APOE Knock-in Mouse Model for Study of Cognitive Function After Cancer Chemotherapy. Neurotox Res :
Rebbeck, Timothy R (see original citation for additional authors) (2018) Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. Hum Mutat 39:593-620
Coia, Heidi; Ma, Ning; Hou, Yanqi et al. (2018) Prevention of Lipid Peroxidation-derived Cyclic DNA Adduct and Mutation in High-Fat Diet-induced Hepatocarcinogenesis by Theaphenon E. Cancer Prev Res (Phila) 11:665-676
Lee, Yichien; Rodriguez, Olga C; Albanese, Chris et al. (2018) Divergent brain changes in two audiogenic rat strains: A voxel-based morphometry and diffusion tensor imaging comparison of the genetically epilepsy prone rat (GEPR-3) and the Wistar Audiogenic Rat (WAR). Neurobiol Dis 111:80-90
Ozawa, Patricia Midori Murobushi; Alkhilaiwi, Faris; Cavalli, Iglenir João et al. (2018) Extracellular vesicles from triple-negative breast cancer cells promote proliferation and drug resistance in non-tumorigenic breast cells. Breast Cancer Res Treat 172:713-723
Ory, Virginie; Kietzman, William B; Boeckelman, Jacob et al. (2018) The PPAR? agonist efatutazone delays invasive progression and induces differentiation of ductal carcinoma in situ. Breast Cancer Res Treat 169:47-57
Edwardson, Matthew A; Zhong, Xiaogang; Fiandaca, Massimo S et al. (2018) Plasma microRNA markers of upper limb recovery following human stroke. Sci Rep 8:12558
Smith, Jill P; Wang, Shangzi; Nadella, Sandeep et al. (2018) Cholecystokinin receptor antagonist alters pancreatic cancer microenvironment and increases efficacy of immune checkpoint antibody therapy in mice. Cancer Immunol Immunother 67:195-207

Showing the most recent 10 out of 1120 publications